ZIM
ICPT

Zacks Investment Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Zacks Investment Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-10,009
Closed -$1.21M – 675
2017
Q2 		$1.21M Buy
+10,009
New +$1.16M 0.03% 327
2016
Q1 		– Sell
-1,407
Closed -$210K – 702
2015
Q4 		$210K Sell
1,407
-2,814
-67% -$476K 0.01% 518
2015
Q3 		$700K Buy
+4,221
New +$929K 0.02% 366

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Zacks Investment Management's ICPT Position: Q3 2017 in Review

Zacks Investment Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2017, closing a stake of 10,009 shares — an estimated $1.21M sold.

Zacks Investment Management first reported a position in ICPT in Q3 2015 and held it in 3 quarters. The position peaked at $1.21M in Q2 2017. 155 funds tracked by Wall St. Rank hold ICPT as of Q3 2017.

  • Zacks Investment Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Zacks Investment Management sold 10,009 Intercept Pharmaceuticals, Inc. shares in Q3 2017, an estimated $1.21M.
  • Zacks Investment Management first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2015 and held it in 3 quarters.
  • Zacks Investment Management's Intercept Pharmaceuticals, Inc. position peaked at $1.21M in Q2 2017.
  • 155 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2017.

Based on Zacks Investment Management's 13F filing for Q3 2017, filed 14 Nov 2017.